

Amy A Habib

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9175411/publications.pdf>

Version: 2024-02-01

35
papers

2,103
citations

279798

23
h-index

414414

32
g-index

35
all docs

35
docs citations

35
times ranked

3970
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance. <i>Neoplasia</i> , 2010, 12, 675-684.	5.3	381
2	Ligand-Independent EGFR Signaling. <i>Cancer Research</i> , 2015, 75, 3436-3441.	0.9	166
3	Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells. <i>Cancer Research</i> , 2006, 66, 867-874.	0.9	149
4	An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases. <i>Nature Communications</i> , 2019, 10, 5108.	12.8	148
5	The Receptor Interacting Protein 1 Inhibits p53 Induction through NF- κ B Activation and Confers a Worse Prognosis in Glioblastoma. <i>Cancer Research</i> , 2009, 69, 2809-2816.	0.9	134
6	The Epidermal Growth Factor Receptor Engages Receptor Interacting Protein and Nuclear Factor- κ B (NF- κ B)-inducing Kinase to Activate NF- κ B. <i>Journal of Biological Chemistry</i> , 2001, 276, 8865-8874.	3.4	116
7	A TNF α -"JNK"-"Ax1"-"ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. <i>Nature Neuroscience</i> , 2017, 20, 1074-1084.	14.8	82
8	TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 2500-2518.	8.2	73
9	Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. <i>Nature Communications</i> , 2014, 5, 5811.	12.8	72
10	The role of NF- κ B in the pathogenesis of glioma. <i>Molecular and Cellular Oncology</i> , 2014, 1, e963478.	0.7	71
11	Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. <i>Nature Communications</i> , 2017, 8, 1913.	12.8	62
12	Elimination of Radiation-Induced Senescence in the Brain Tumor Microenvironment Attenuates Glioblastoma Recurrence. <i>Cancer Research</i> , 2021, 81, 5935-5947.	0.9	62
13	Hippocampal Sclerosis in Dementia, Epilepsy, and Ischemic Injury: Differential Vulnerability of Hippocampal Subfields. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014, 73, 136-142.	1.7	57
14	RIP1 Activates PI3K-Akt via a Dual Mechanism Involving NF- κ B-Mediated Inhibition of the mTOR-S6K-IRS1 Negative Feedback Loop and Down-regulation of PTEN. <i>Cancer Research</i> , 2009, 69, 4107-4111.	0.9	53
15	Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma. <i>Molecular Cancer Research</i> , 2016, 14, 928-940.	3.4	53
16	EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. <i>Nature Cancer</i> , 2020, 1, 394-409.	13.2	51
17	Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. <i>Nature Nanotechnology</i> , 2022, 17, 206-216.	31.5	46
18	Opposing Effect of EGFRWT on EGFRvIII-Mediated NF- κ B Activation with RIP1 as a Cell Death Switch. <i>Cell Reports</i> , 2013, 4, 764-775.	6.4	38

#	ARTICLE	IF	CITATIONS
19	Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment. <i>Neoplasia</i> , 2021, 23, 189-196.	5.3	38
20	High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II&III astrocytomas and oligoastrocytomas. <i>Journal of Neuro-Oncology</i> , 2014, 117, 183-189.	2.9	34
21	Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 542-548.	1.7	34
22	Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways. <i>Molecular Cancer Research</i> , 2003, 1, 219-33.	3.4	33
23	Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis. <i>Journal of Neuro-Oncology</i> , 2017, 133, 183-192.	2.9	30
24	Radiation-Induced DNA Damage Cooperates with Heterozygosity of TP53 and PTEN to Generate High-Grade Gliomas. <i>Cancer Research</i> , 2019, 79, 3749-3761.	0.9	23
25	Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1529-1539.	1.2	21
26	Cytoplasmic TRADD Confers a Worse Prognosis in Glioblastoma. <i>Neoplasia</i> , 2013, 15, 888-897.	5.3	16
27	Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential. <i>Molecular Imaging</i> , 2017, 16, 153601211770872.	1.4	15
28	Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1904-1915.	4.1	15
29	The death domain-containing kinase RIP1 regulates p27 Kip1 levels through the PI3K&Akt&forkhead pathway. <i>EMBO Reports</i> , 2008, 9, 766-773.	4.5	13
30	Improved protein arrays for quantitative systems analysis of the dynamics of signaling pathway interactions. <i>Proteome Science</i> , 2011, 9, 53.	1.7	8
31	Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. <i>Nature Communications</i> , 2021, 12, 7014.	12.8	6
32	The receptor interacting protein 1 mediates a link between NF&B and PI3-kinase signaling. <i>Cell Cycle</i> , 2009, 8, 2671-2672.	2.6	3
33	Analysis of Constitutive EGFR Signaling Regulating IRF3 Transcriptional Activity in Cancer Cells. <i>Methods in Molecular Biology</i> , 2017, 1652, 183-189.	0.9	0
34	DRES-06. PRIMARY RESISTANCE TO EGFR INHIBITION IN GLIOBLASTOMA IS MEDIATED BY A&TNF-JNK-AxI-ERK SIGNALING AXIS. <i>Neuro-Oncology</i> , 2017, 19, vi65-vi65.	1.2	0
35	DRES-17. ACTIVATION OF FGF SIGNALING PATHWAY CONFERS RESISTANCE TO EGFR INHIBITION IN GBM. <i>Neuro-Oncology</i> , 2018, 20, vi79-vi79.	1.2	0